Individual generic drug information

gliclazide

Reference monograph

Part of registered formulation

GLICLAZIDE

Reference record: Gliclazide
Source: BNF 80 (2020–2021)
Printed source pages: 770
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Gliclazide only.

Indications And Dose

Type 2 diabetes mellitus ▶BY MOUTH USING IMMEDIATE-RELEASE MEDICINES ▶Adult: Initially 40–80 mg daily, adjusted according to response, increased if necessary up to 160 mg once daily, dose to be taken with breakfast, doses higher than 160 mg to be given in divided doses; maximum 320 mg per day ▶BY MOUTH USING MODIFIED-RELEASE MEDICINES ▶Adult: Initially 30 mg daily, dose to be taken with breakfast, adjust dose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120 mg per day DOSE EQUIVALENCE AND CONVERSION ▶Gliclazide modiﬁed release 30 mg may be considered to be approximately equivalent in therapeutic effect to standard formulation gliclazide 80 mg.

Source page 770

Contra Indications

Avoid where possible in Acute porphyrias p. 1120

Source page 770

Safety

Extracted information for Gliclazide only.

Interactions

→Appendix 1: sulfonylureas

Source page 770

Side Effects

Anaemia. angioedema. dyspepsia. gastrointestinal disorder. hypersensitivity vasculitis. hyponatraemia. severe cutaneous adverse reactions (SCARs)

Source page 770

Pregnancy

The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.

Source page 770

Breast Feeding

Avoid—theoretical possibility of hypoglycaemia in the infant.

Source page 770

Renal Impairment

If necessary, gliclazide which is principally metabolised in the liver, can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.

Source page 770

Dose and formulations

Extracted information for Gliclazide only.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Modified-release tablet CAUTIONARY AND ADVISORY LABELS 25 ▶Bilxona (Accord Healthcare Ltd) Gliclazide 30 mg Bilxona 30mg modified-release tablets | 28 tablet P £1.63 DT = £2.81 | 56 tablet P £3.27 Gliclazide 60 mg Bilxona 60mg modified-release tablets | 28 tablet P £3.27 DT = £4.77 | 56 tablet P £6.55 ▶Dacadis MR (Mylan) Gliclazide 30 mg Dacadis MR 30mg tablets | 28 tablet P £2.81 DT = £2.81 | 56 tablet P £5.62 ▶Diamicron MR (Servier Laboratories Ltd) Gliclazide 30 mg Diamicron 30mg MR tablets | 28 tablet P £2.81 DT = £2.81 | 56 tablet P £5.62 ▶Edicil MR (Teva UK Ltd) Gliclazide 30 mg Edicil MR 30mg tablets | 28 tablet P £2.62 DT = £2.81 | 56 tablet P £5.24 ▶Laaglyda MR (Consilient Health Ltd) Gliclazide 60 mg Laaglyda MR 60mg tablets | 28 tablet P £4.77 DT = £4.77 ▶Lamzarin (Key Pharmaceuticals Ltd) Gliclazide 30 mg Lamzarin 30mg modified-release tablets | 28 tablet P £2.81 DT = £2.81 | 56 tablet P £5.62 Gliclazide 60 mg Lamzarin 60mg modified-release tablets | 28 tablet P £4.77 DT = £4.77 ▶Nazdol MR (Consilient Health Ltd) Gliclazide 30 mg Nazdol MR 30mg tablets | 28 tablet P £2.35 DT = £2.81 | 56 tablet P £4.92 ▶Vamju (Advanz Pharma) Gliclazide 30 mg Vamju 30mg modified-release tablets | 28 tablet P £1.64 DT = £2.81 | 56 tablet P £3.28 Gliclazide 60 mg Vamju 60mg modified-release tablets | 28 tablet P £3.28 DT = £4.77 ▶Ziclaseg (Lupin Healthcare (UK) Ltd) Gliclazide 30 mg Ziclaseg 30mg modified-release tablets | 28 tablet P £2.38 DT = £2.81 | 56 tablet P £4.77 ▶Zicron PR (Bristol Laboratories Ltd) Gliclazide 30 mg Zicron PR 30mg tablets | 28 tablet P £1.95 DT = £2.81 | 56 tablet P £3.90 Tablet ▶Gliclazide (Non-proprietary) Gliclazide 40 mg Gliclazide 40mg tablets | 28 tablet P £3.19 DT = £1.51 Gliclazide 80 mg Gliclazide 80mg tablets | 28 tablet P £1.80 DT = £1.07 | 60 tablet P £0.81–£2.29 ▶Diamicron (Servier Laboratories Ltd) Gliclazide 80 mg Diamicron 80mg tablets | 60 tablet P £4.38 ▶Zicron (Bristol Laboratories Ltd) Gliclazide 40 mg Zicron 40mg tablets | 28 tablet P £3.36 DT = £1.51 eiiii F 747

Source page 770

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

Initially 40–80 mg daily, adjusted according to

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 770

Adults

First line only; read the complete Indications and dose section above.

Initially 30 mg daily, dose to be taken with

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 770

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

gliclazide

Reference monograph

Part of registered formulation

GLICLAZIDE

Reference record: Gliclazide
Source: BNF 80 (2020–2021)
Printed source pages: 770
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Gliclazide only.

Indications And Dose

Source page 770

Contra Indications

Avoid where possible in Acute porphyrias p. 1120

Source page 770

Safety

Extracted information for Gliclazide only.

Interactions

→Appendix 1: sulfonylureas

Source page 770

Side Effects

Anaemia. angioedema. dyspepsia. gastrointestinal disorder. hypersensitivity vasculitis. hyponatraemia. severe cutaneous adverse reactions (SCARs)

Source page 770

Pregnancy

The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.

Source page 770

Breast Feeding

Avoid—theoretical possibility of hypoglycaemia in the infant.

Source page 770

Renal Impairment

If necessary, gliclazide which is principally metabolised in the liver, can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.

Source page 770

Dose and formulations

Extracted information for Gliclazide only.

Medicinal Forms

Source page 770

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

Initially 40–80 mg daily, adjusted according to

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 770

Adults

First line only; read the complete Indications and dose section above.

Initially 30 mg daily, dose to be taken with

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 770

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.